HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

MDX-060. Medarex.

Abstract
Medarex is developing the antibody MDX-060 for the potential treatment of CD30+ lymphomas, such as Hodgkin's disease and anaplastic large cell lymphomas. Phase I/II clinical trials were underway by December 2002.
AuthorsXiu Feng Hu, Pei Xiang Xing
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 6 Issue 12 Pg. 1266-71 (Dec 2005) ISSN: 1472-4472 [Print] England
PMID16370393 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Ki-1 Antigen
  • iratumumab
Topics
  • Animals
  • Antibodies, Monoclonal
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Clinical Trials as Topic
  • Drug Screening Assays, Antitumor
  • Hodgkin Disease (drug therapy, immunology)
  • Humans
  • Ki-1 Antigen (immunology)
  • Lymphoma, Large B-Cell, Diffuse (drug therapy, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: